Research Reports


Home » Reports » Cancer Immunotherapy Market
Market Research Report

Cancer Immunotherapy Market By Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, Others), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostrate Cancer, Head & Neck Cancer, Gastric Cancer, Leukemia, Other Cancer Types), By End-User ( Hospitals, Research Centres, Clinics)- Global Demand Analysis & Opportunity Outlook 2027

Published On : 04:13 AM, 8th October, 2018 REP-ID-1087 Category: Healthcare

Global cancer immunotherapy Market Overview

Cancer immunotherapy is the use of immune system to treat cancer. Multiple antibody therapies are approved in various jurisdictions to treat a wide range of cancers. The future of the cancer immunotherapy market looks promising, as a number of new and innovative therapies are coming on to the market. Monoclonal antibodies (mAbs) held the largest market share.

Market Size & Forecast

Global Cancer Immunotherapy market is predicted to grow at a strong compound annual growth rate (CAGR) over the forecast period  with 12.6% in the second half of the forecast period. Global cancer immunotherapy market is mainly expanding on the back of expanding immunotherapy market. The market of cancer immunotherapy is projected to reach at a notable valuation by the end of forecast period.

The approval of advance therapeutics and personalized medicine is changing the preferences from conventional chemotherapies to immunotherapies. Amplified research & development finance from both government and private entities to address the increasing frequency of cancer will drive demand and emphasize the progress in the market.

On the basis of regional platform, global cancer immunotherapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

Asia Pacific is predicted to encounter the speediest advance as more multinational companies invest in the region through mergers and attainments to hold their market share and thus expand their product portfolio.

Europe holds the second largest share of the market as a result of increasing focus of various government agencies on the treatment of disease like cancer.

Market Segmentation

Our-in depth analysis of the global cancer immunotherapy market includes the following segments:

 By Technology

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

By Application

  • Lung Cancer
  •  Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Gastric Cancer
  • Leukemia
  • Other Cancer Types

By End-User

  • Hospitals
  • Research Centers
  • Clinics

By Region

Global cancer immunotherapy market is further classified on the basis of region as follows:

  • North America (U.S. & Canada)
  • Latin America (Brazil, Mexico, Rest of Latin America
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, Rest of Europe)
  • Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of Asia)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

Growth Drivers & Challenges

Faster drug approval processes, increasing prevalence of cancer, and rising adoption of targeted therapies are the primary growth drivers for global cancer immunotherapy market that is driving the market. Frequent introduction of new drugs has resulted in rise in competition. Immunomodulatory drugs, such as thalidomide, lenalidomide, and pomalidomide, were the best treatment options available in the past few years. Launching new drug classes, such as monoclonal antibodies and HDAC inhibitors, is expected to initiate new trends in the market.

Rising R&D in cancer immunotherapy is resulting in the introduction of advanced treatment options that are increasingly effective and efficient. Ongoing studies on similar drugs designed to minimize side effects are expected to propel the market for these drug classes. Healthcare providers recommending more efficient targeted therapies as opposed to conventional modes of therapy can drive the market as well in the forecast period of 2017-2027.

However, challenges in clinical trials, changes in compensation policies and cost constraints will restrain the growth of global cancer immunotherapy market in the future. Moreover, the obstacles contributed by the governments in regulating alternative therapies or drugs for cancer treatment due to factors such as inconsistency and confusion in hospital policies regarding CAM (Complimentary & Alternative Medicine) since universally accepted guidelines have not been established for the use of these therapies can create challenges in the market thus slowing down the expected growth.

Key Players

  • AstraZeneca
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Merck & Co.
  • Novartis
  • Adaxis Inc
  • Bristol-Myers Squibb (BMS)
  • Bayer AG
  • Roche
  • Eli Lilly and Co.
  • Medtronic Plc.
  • Pfizer Inc

Scope & Context

Overview of the Parent Market

Analyst View


The global security solution market is segmented as follows:

  • By Component Market Size & Y-O-Y Growth Analysis
  • By Sales Channel Market Size & Y-O-Y Growth Analysis
  • By Region Market Size & Y-O-Y Growth Analysis

Market Dynamics

Supply & Demand Risk

Competitive Landscape

Porter’s Five Force Model

Geographical Economic Activity

Key Players (respective SWOT Analysis) and their Strategies and Product Portfolio

Recent Trends and Developments

Industry Growth Drivers and Challenges

Key Information for Players to establish themselves in current dynamic environment

key Answers




    Direct access to analyst to help you understand the market in a better way to handle your critical question


    Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved


    Get 10% free customization


    Great focus on accuracy and quality of the research

Connect With Us

Call us

(U.S.) - +1 646 586 9123
(Canada) - +1 437 889 3230
(U.K.) - +44 203 608 5919
(India) - + 91 120 660 5495

Delivery Center

Ansal Corporate Park, Plot no 7A/1,
Tower A1,
Sector 142 Noida., 201301 India

US Office

77 Water Street 8th Floor,
New York, New York, 10005
Phone : +1 646 586 9123

Canada (Toronto)

Phone : +1 437 889 3230

UK Office (London)

Phone : +44 203 608 5919

Subscribe To Our Newsletters

Copyright © 2018 Research Nester. All rights reserved